ATC Group: J01G Aminoglycoside antibacterials

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J01G in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J01 Antibacterials for systemic use
3 J01G Aminoglycoside antibacterials

Group J01G contents

Code Title
J01GA Streptomycins
J01GB Other aminoglycosides

Active ingredients in J01G

Active Ingredient

Amikacin is an antibiotic used for a number of bacterial infections. Amikacin works by blocking the function of the bacteria’s 30S ribosomal subunit, making it unable to produce proteins.

Gentamicin is usually bactericidal in action. Although the exact mechanism of action has not been fully elucidated, the drug appears to inhibit protein synthesis in susceptible bacteria by irreversibly binding to 30S ribosomal subunits.

Kanamycin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth.

Neomycin is an aminoglycoside antibiotic and acts by binding to polysomes, inhibiting protein synthesis and generating errors in the transcription of the genetic code.

Plazomicin is an aminoglycoside antibacterial. It is used for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible microorganism(s): Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae.

Streptomycin is a broad spectrum aminoglycoside antibiotic derived from Streptomyces griseus with antibacterial activity. It acts by interfering with normal protein synthesis. Streptomycin is typically used for treatment of active tuberculosis, always in combination with other antituberculosis agents.

Tobramycin is an aminoglycoside antibiotic produced by Streptomyces tenebrarius. It acts primarily by disrupting protein synthesis leading to altered cell membrane permeability, progressive disruption of the cell envelope and eventual cell death. It is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations.

Related product monographs

Document Type Information Source  
 AMIKIN INJECTION Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 ARIKAYCE Inhalation suspension MPI, US: SPL/PLR FDA, National Drug Code (US)
 NIVEMYCIN Tablets MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 SELEMYCIN Solution for injection/infusion MPI, EU: SmPC Υπουργείο Υγείας (CY)
 TOBI Podhaler Inhalation powder, hard capsule MPI, EU: SmPC European Medicines Agency (EU)
 TYMBRINEB Nebuliser solution MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)